Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director · Chief Financial Officer | November 20, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PharmaCyte Biotech, Inc.
Report date November 20, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-11-20 | Direct | 85,000 |
Reported balance
After 2023-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-20 · Grant · Acquired 85,000 · Balance 85,000 F1: The options vest 50% on November 20, 2023 and 50% on November 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 50% on November 20, 2023 and 50% on November 20, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2023 Filed Nov 22, 2023 22:01 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001683168-23-008432 · ownership.xml · derivative · entry 1 Trujillo Carlos · CIK 0001464520 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-11-20 F1 · derivative.exercise_date: The options vest 50% on November 20, 2023 and 50% on November 20, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.